Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FY 2006 appropriation for effectiveness research

Executive Summary

House/Labor, HHS & Education Subcommittee mark for fiscal 2006 appropriations budgets $15 mil. for AHRQ to perform comparative effectiveness research. AHRQ received $15 mil. for the program in FY 2005 (1"The Pink Sheet" Sept. 20, 2004, p. 14)...

You may also be interested in...



Rx Comparative Effectiveness Research Funds Included In HHS Approps Bill

Funding for prescription drug comparative effectiveness research is included in the HHS fiscal year 2005 appropriations bill reported to the full Senate Sept. 15

Pfizer Eyes EU Pegfilgrastim Roll-Out By 1 April As US Launch Is Confirmed

Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.

Samsung Bioepis Opens New HQ To Drive Next-Generation Biosimilars

With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel